A Randomized, Blinded, Multicenter Trial of Lipid-Associated Amphotericin B Alone versus in Combination with an Antibody-Based Inhibitor of Heat Shock Protein 90 in Patients with Invasive Candidiasis
Top Cited Papers
Open Access
- 15 May 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (10) , 1404-1413
- https://doi.org/10.1086/503428
Abstract
Background. Mycograb (NeuTec Pharma) is a human recombinant monoclonal antibody against heat shock protein 90 that, in laboratory studies, was revealKeywords
This publication has 39 references indexed in Scilit:
- Candidemia is Costly--Plain and SimpleClinical Infectious Diseases, 2005
- The Epidemiology and Attributable Outcomes of Candidemia in Adults and Children Hospitalized in the United States: A Propensity AnalysisClinical Infectious Diseases, 2005
- Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trialThe Lancet, 2005
- Excess Mortality, Hospital Stay, and Cost Due to Candidemia: A Case-Control Study Using Data From Population-Based Candidemia SurveillanceInfection Control & Hospital Epidemiology, 2005
- Toward more effective antifungal therapy: the prospects of combination therapyBritish Journal of Haematology, 2004
- Guidelines for Treatment of CandidiasisClinical Infectious Diseases, 2004
- Attributable Mortality of Nosocomial Candidemia, RevisitedClinical Infectious Diseases, 2003
- A Prospective Observational Study of Candidemia: Epidemiology, Therapy, and Influences on Mortality in Hospitalized Adult and Pediatric PatientsClinical Infectious Diseases, 2003
- Amphotericin B: Time for a New "Gold Standard"Clinical Infectious Diseases, 2003
- Comparison of Caspofungin and Amphotericin B for Invasive CandidiasisNew England Journal of Medicine, 2002